Potent Antitumor Activity of Double-Regulated Oncolytic Adenovirus-Mediated ST13 for Colorectal Cancer

Strategic Insights -

Scientists in Hangzhou, People's Republic of China, have made a groundbreaking discovery in the field of cancer gene therapy. They have developed a highly effective treatment for colorectal cancer by inserting the suppression of tumorigenicity 13 (ST13) gene into a double-regulated oncolytic adenovirus, known as SG500. This innovative approach has shown potent antitumor activity in vitro and in vivo, with significant implications for the treatment of colorectal cancer.

Key Takeaways:

  • The researchers used a double-regulated oncolytic adenovirus, SG500, to deliver the ST13 gene to colorectal cancer cells in vitro and in vivo.
  • The ST13-expressing oncolytic adenovirus, SG500-ST13, showed potent antitumor activity against colorectal carcinoma cell lines SW620 and HCT116, and the lung fibroblast cell line WI38.
  • The researchers used various methods, including crystal violet staining, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, Hoechst staining, and TdT-mediated dUTP-biotin nick-end labeling (TUNEL) method, to assess the antitumor effects of SG500-ST13.
  • Immunohistochemical study was also carried out to further identify the antitumor effects of SG500-ST13 on HCT116 xenografts in Balb/c nude mice.
  • The researchers published their study in Cancer Science, a peer-reviewed journal, and concluded that the ST13-expressing oncolytic adenovirus, SG500-ST13, has potent antitumor activity against colorectal cancer.

Statistics:

  • The researchers used crystal violet staining to detect the cytopathic effect in cells, and the MTT assay to assess cell viability.
  • Hoechst staining was used to confirm the effect of apoptosis induced by SG500-ST13, and TUNEL method was used to assess the induction of cell death.
  • Hematoxylin-eosin staining was used to assess the induction of cell death in HCT116 xenografts in Balb/c nude mice.
  • The researchers published their study in the Journal of Cancer Science, Vol. 100, No. 4, 2009.

Sources:

  • D.E.B. Yu, et al., "Potent antitumor activity of double-regulated oncolytic adenovirus-mediated ST13 for colorectal cancer," Cancer Science, 2009; 100(4): 678-83.
  • Cancer Gene Therapy Week, "Cancer Gene Therapy: Breakthroughs and Discoveries," 2009.
  • NewsRx.com, "Cancer Gene Therapy Week," 2009.